PFE

Pfizer Invites Public to View and Listen to Webcast of January 30 Conference Call with Analysts

Retrieved on: 
Tuesday, December 19, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, PFE, EST, Webcast, Performance report, Inc., Pfizer

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, January 30, 2024.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, January 30, 2024.
  • To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors .
  • Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today.
  • You can also listen to the conference call by dialing either 800-456-4352 in the United States and Canada or 785-424-1086 outside of the United States and Canada.

Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers third sales milestone payment for the region from Pfizer this year

Retrieved on: 
Monday, November 20, 2023
NYSE, PFE, Patient, Pharmaceutical industry, Isavuconazonium, Pfizer, Allschwil

David Veitch, Basilea’s Chief Executive Officer, stated: “This marks the third sales milestone payment for Asia Pacific and China this year.

Key Points: 
  • David Veitch, Basilea’s Chief Executive Officer, stated: “This marks the third sales milestone payment for Asia Pacific and China this year.
  • It highlights that Cresemba continues to serve a high medical need and also reflects the significant commercial potential of Cresemba in this region.
  • Cresemba is approved in 76 countries to date and is currently marketed in 71 countries, including the United States, most EU member states and additional countries inside and outside of Europe.
  • According to the latest available market data, total global in-market sales of Cresemba in the twelve months between July 2022 and June 2023 amounted to USD 421 million, a 19 percent growth year-on-year.1

PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) Approved by FDA as the First and Only ADC Plus PD-1 to Treat Advanced Bladder Cancer

Retrieved on: 
Friday, December 15, 2023
Research, FDA, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Cisplatin, NYSE, PFE, Food, Platinum, Progression-free survival, Carcinoma, ADC, ESMO, Patient, PFS, Astellas Pharma, Pembrolizumab, PD-1, Brentuximab vedotin, Survival, Death, Pfizer, Congress, OS, Inc., Confidence interval, Pharmaceutical industry, Dietary supplement

This combination is the first approved to offer an alternative to platinum-containing chemotherapy, the current standard of care in first-line la/mUC.

Key Points: 
  • This combination is the first approved to offer an alternative to platinum-containing chemotherapy, the current standard of care in first-line la/mUC.
  • Findings from EV-302 were presented at the European Society for Medical Oncology (ESMO) Congress 2023 .
  • “In the Phase 3 EV-302 study, the combination of PADCEV and pembrolizumab demonstrated survival benefit for patients with advanced bladder cancer, nearly doubling median OS and median PFS compared with chemotherapy.
  • Our network is thrilled that the FDA has approved a new treatment option, and we are excited about the hope it will provide to members of the bladder cancer patient community.”

Pfizer Declares First-Quarter 2024 Dividend

Retrieved on: 
Thursday, December 14, 2023
Biotechnology, General Health, Pharmaceutical, Health, Common stock, 341st Air Refueling Squadron, Pfizer, NYSE, Inc., PFE, Holding company, Management

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared an increase in the quarterly cash dividend on the company’s common stock to $0.42 for the first-quarter 2024 dividend, payable March 1, 2024, to holders of the Common Stock of record at the close of business on January 26, 2024.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared an increase in the quarterly cash dividend on the company’s common stock to $0.42 for the first-quarter 2024 dividend, payable March 1, 2024, to holders of the Common Stock of record at the close of business on January 26, 2024.
  • The first-quarter 2024 cash dividend will be the 341st consecutive quarterly dividend paid by Pfizer.
  • “We are pleased to increase our quarterly dividend, which represents our fifteenth year of consecutive dividend increases,” said Dr. Albert Bourla, Pfizer Chairman and Chief Executive Officer.
  • “Our ongoing increases have demonstrated Pfizer’s commitment to returning value to our shareholders and are a key part of our capital allocation strategy.”

Pfizer Completes Acquisition of Seagen

Retrieved on: 
Thursday, December 14, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, NYSE, Research, Policy, Acquisition, PFE, Spacecraft, LLP, Avelumab, Investment, ADC, Brentuximab vedotin, Antibody-drug conjugate, Protein engineering, Sullivan & Cromwell, Science, Centerview Partners, Oliver Cromwell, AACR, Cancer, Death, Financial toxicity, Communication, Federal Trade Commission, Growth, Guggenheim Partners, Inc., Arnold & Porter, Conjugation, Education, Pharmaceutical industry, Fine chemical, Pfizer, Seagen

Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN), a global biotechnology company that discovers, develops and commercializes transformative cancer medicines.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Seagen Inc. (NASDAQ: SGEN), a global biotechnology company that discovers, develops and commercializes transformative cancer medicines.
  • Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion.
  • With the addition of Seagen, Pfizer’s Oncology pipeline has doubled in size with 60 programs spanning multiple modalities, including ADCs, small molecules, bispecifics and other immunotherapies.
  • “This is a great day for Pfizer, and, more importantly, for people living with cancer, as we bring together the game-changing science and top talent of Seagen and Pfizer to form a leading Oncology organization,” said Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer.

Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen

Retrieved on: 
Tuesday, December 12, 2023
Biotechnology, Pharmaceutical, Health, Oncology, Webcast, Pfizer, Research, Acquisition, NYSE, Policy, PFE, Hart–Scott–Rodino Antitrust Improvements Act, Avelumab, Patient, Science, Vaccine, Cancer, Communication, Federal Trade Commission, EST, Inc., AACR, Education, Pharmaceutical industry, Seagen

Pfizer and Seagen have now received all required regulatory approvals to complete the acquisition.

Key Points: 
  • Pfizer and Seagen have now received all required regulatory approvals to complete the acquisition.
  • Pfizer expects to close the acquisition of Seagen on December 14, 2023, subject to the satisfaction of other customary closing conditions.
  • Pfizer also announces changes in its commercial organization to incorporate Seagen and improve focus, speed and quality of execution.
  • During the call Pfizer will discuss the Seagen acquisition, new commercial organization, and provide full-year 2024 financial guidance.

FDA and EMA Accept Marstacimab Regulatory Submissions for the Treatment of Hemophilia A and B

Retrieved on: 
Monday, December 11, 2023
Biotechnology, FDA, Pharmaceutical, Health, Medicine, Safety, NYSE, Senior, PFE, Food, TFPI, Haemophilia, BLA, European Medicines Agency, European Commission, ASH, MAA, EMA, Civil service commission, Patient, Research and development, Research, Internal medicine, FIX, Rusyns, Exposition, Factor IX, Hemostasis, Development, Factor VIII, PDUFA, Society, Inc., Infection, Pharmaceutical industry, Pfizer

The European marketing authorization application (MAA) for marstacimab also passed validation and is currently under review by the European Medicines Agency (EMA).

Key Points: 
  • The European marketing authorization application (MAA) for marstacimab also passed validation and is currently under review by the European Medicines Agency (EMA).
  • If approved in the U.S. and EU, marstacimab is expected to become the first once-weekly subcutaneous treatment for people living with hemophilia B and the first treatment administered as a flat dose for people living with hemophilia A or B.
  • For appropriate patients living with hemophilia A and B, the goal of this treatment is to prevent potentially life-threatening bleeds with a once-weekly, subcutaneous flat-dose administration.
  • The submissions for marstacimab are based on efficacy and safety data from the Phase 3 BASIS trial ( NCT03938792 ).

Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B

Retrieved on: 
Sunday, December 10, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, Safety, NYSE, Senior, PFE, Haemophilia, ASH, Risk, Research and development, Research, Internal medicine, FIX, ABR, Rusyns, Factor IX, Bleeding, Development, ATP, Factor VIII, Society, Inc., Infection, Pharmaceutical industry, Pfizer

The results from the BASIS trial demonstrated a statistically significant and clinically meaningful effect on annualized bleeding rate (ABR).

Key Points: 
  • The results from the BASIS trial demonstrated a statistically significant and clinically meaningful effect on annualized bleeding rate (ABR).
  • The findings were presented today at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego.
  • In addition to the BASIS study, fidanacogene elaparvovec and giroctocogene fitelparvovec are investigational gene therapy treatments being studied for the treatment of adults living with hemophilia B and hemophilia A, respectively.
  • Updated data from both gene therapy programs, including an oral presentation of four-year results from Pfizer’s Phase 1/2 study of giroctocogene fitelparvovec in adults living with severe hemophilia A, will be presented at the ASH meeting.

European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma

Retrieved on: 
Friday, December 8, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Multiple myeloma, Lymphocytopenia, Fever, Bispecific monoclonal antibody, NYSE, Cytokine release syndrome, PFE, European Medicines Agency, Rash, European Commission, Pneumonia, Upper respiratory tract infection, CRS, Risk, Febrile neutropenia, Fatigue, EMA, Civil service commission, Patient, Sepsis, Thrombocytopenia, Probability, Periodic breathing, Appetite, CHMP, B-cell maturation antigen, Injection site reaction, Committee, Neutropenia, Diarrhea, Nausea, Arthralgia, RRMM, Anemia, BCMA, Immunotherapy, Hypokalemia, Urinary tract infection, Inc., HIV disease progression rates, Vaccine, Pharmaceutical industry, Pfizer, Nature Medicine

Pfizer Inc. (NYSE:PFE) today announced the European Commission (EC) has granted conditional marketing authorization for ELREXFIO® (elranatamab).

Key Points: 
  • Pfizer Inc. (NYSE:PFE) today announced the European Commission (EC) has granted conditional marketing authorization for ELREXFIO® (elranatamab).
  • "More than 50,000 Europeans are diagnosed with multiple myeloma each year, and too often, they face relapse and treatment resistance,” said Chris Boshoff, Chief Oncology Research and Development Officer and Executive Vice President, Pfizer.
  • The conditional marketing authorization for ELREXFIO is valid in all 27 EU member states as well as Iceland, Liechtenstein, and Norway.
  • This authorization follows the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) recommendation for a conditional marketing authorization on October 12, 2023.

Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity

Retrieved on: 
Friday, December 1, 2023
Research, Diabetes, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Vomiting, Safety, NYSE, PFE, FPG, Fasting, Incidence, Plasma, Liver, Metformin, Patient, Journal, Nature, American Medical Association, Extrapyramidal system, Obesity, Diarrhea, Nausea, Pfizer, Human, Inc., Pharmaceutical industry, Glycated hemoglobin

Pfizer Inc. (NYSE: PFE) today announced topline data from the Phase 2b clinical trial ( NCT04707313 ) investigating its oral Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate, danuglipron (PF-06882961), in adults with obesity and without type 2 diabetes.

Key Points: 
  • Pfizer Inc. (NYSE: PFE) today announced topline data from the Phase 2b clinical trial ( NCT04707313 ) investigating its oral Glucagon-like peptide-1 receptor agonist (GLP-1RA) candidate, danuglipron (PF-06882961), in adults with obesity and without type 2 diabetes.
  • The study met its primary endpoint demonstrating statistically significant change in body weight from baseline.
  • Placebo-adjusted reductions in mean body weight ranged from -8% to -13% at 32 weeks and -5% to -9.5% at 26 weeks.
  • In both populations, danuglipron demonstrated a safety and tolerability profile consistent with the mechanism of action.